Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Slide 48 Key Novo Nordisk diabetes care products remain broadly available in the USA Value market shares of key Novo Nordisk products in the USA Value market share VictozaⓇ TresibaⓇ NovoLogⓇ % share of unrestricted market access of key Novo Nordisk products in the USA Unrestricted Market access VictozaⓇ TresibaⓇ NovoLogⓇ - LevemirⓇ 80% 60% 40% 20% 0% Feb 2015 Source: IQVIA NSP Feb 2018; LevemirⓇ 100% 80% 60% 40% 20% 0% Feb 2018 Feb 2015 Feb 2018 Note: Market shares: NovoLogⓇ®: share of rapid acting insulin segment; Levemir®: share of basal insulin segment; TresibaⓇ share of basal insulin segment; VictozaⓇ: share of GLP-1 segment Source: FingerTip Formulary bridge, Feb 2018 Nomenclature and Xponent PlanTrak,; only considers bridged volume; excludes cash and mail order data; changing diabetes® Note: Unrestricted access excludes prior authorisation, step edits and other restrictions LevemirⓇ access based on FlexTouch® Pen; NovoLog® access based on FlexPen®; only considers bridged volume; TresibaⓇ launched in January 2016 novo nordisk

View entire presentation